Beyond the Shadows: Transforming Human Metapneumovirus Management with Next Generation Therapeutics and Vaccines

Abstract

The respiratory virus Human Metapneumovirus (HMPV) spreads worldwide yet infects entire age ranges and becomes specifically dangerous for newborns and senior populations together with immune-compromised patients. HMPV seasonally breaks out during late winter and early spring causing healthcare facilities to admit patients and creating additional treatment expenses. HMPV targets respiratory epithelium cells leading to both inflammatory responses and immune-related defense evasion. The fusion protein (F) together with glycoprotein (G) assists virus entry into cells and subdues immune responses which allows the virus to persist for long periods while causing respiratory symptoms. There exists no particular antiviral therapy nor vaccine for this disease. Medical treatment primarily consists of oxygen therapy along with symptom-based therapies. The experimental treatments of ribavirin along with immunoglobulins prove to have inadequate therapeutic impact. Research now concentrates on extending monoclonal antibodies for treatment alongside RNA-based antivirals alongside new therapies that target the human body. Research on vaccine development has achieved promising early trial results with two main candidates: live-attenuated versions and vector-based platforms. Multiple hurdles exist in developing vaccines as well as viral mutation patterns and the duration of acquired vaccine immunity. The healthcare community requires additional research to develop new diagnostic tests and targeted treatment methods and vaccines for effective combating of HMPV. To combat this emerging pathogen both medical trial testing must speed up and scientists from around the world need to work together.

Keywords

Introduction

Human metapneumovirus (HMPV) is a common respiratory tract infection affecting children, adults, elderly, and those with impaired immune systems. It causes pneumonia, bronchiolitis, and asthma exacerbations, with supportive care interventions included in treatment [1] Human metapneumovirus (hMPV), identified in 2001, primarily causes respiratory tract infections in young children, elderly individuals, and those with weakened immune systems [2]. Despite its relatively recent testing method, human metapneumovirus (hMPV) is the leading cause of acute respiratory tract infections (ARTIs) in children worldwide, contributing to cancer, chronic obstructive pulmonary illnesses and asthma[3]. We recognized and explained illness characteristics for a panel of HMPV isolates from all four genetic groupings in our investigation. We found a number of virulent isolates that might kill mice and cause serious illness. In vitro and in vivo, virulent HMPV isolates were associated with substantially boosted production of proinflammatory cytokines and enhanced secretion of type I and type III IFN (IFN). With no effect on viral replication, type I IFN signaling inhibition decreased the disease's path. On the other hand, type III IFN signaling inhibition or genetic ablation partially restored viral replication but had no effect on pathogenesis. As a team, these findings show that type I and type III IFN play different roles in HMPV pathogenesis and immunity [4].

EPIDEMIOLOGY

Pneumonia, influenza, and influenza-like disorders rank sixth in terms of causes of death worldwide, making respiratory tract infections a serious health problem. Even though these diseases are common, the etiological agent causing them is frequently unknown, which raises the possibility that unidentified microorganisms are circulating and causing the illness [5]. the Human Metapneumovirus (HMPV) genotypic diversity and epidemiology in Beijing, China, among children admitted to hospitals with acute respiratory tract infections (ARTIs)[6].HMPV is a negative-sense RNA virus with eight genes and nine proteins. It is categorized into two major genetic groups, A and B, and five lineages. Clinical courses and genotypes may not be directly related, but antigenic variation is observed across various hMPV genetic lineages in animal models [7]. There was no discernible variation in prevalence by sex, according to the study, and the majority of HMPV-positive individuals solely had HMPV. The most common pathogen to be codetected was RSV, with an 18.4% codetection rate. HCoV-OC43, MP, HBoV, ADV, HRV, InfA, PIV2, and PIV3 all had detection rates above 5%, indicating that a variety of respiratory infections may coexist with HMPV in juvenile ARI patients[8].

CHILDREN:

While they persist throughout early childhood, hospitalization rates for HMPV infection are highest in the first year of life. HMPV hospitalization peaks between 6 and 12 months of age, which is later than RSV hospitalization peaks (2–3 months), according to many studies [9].Several HMPV subgroups will frequently be in circulation throughout the course of a year. One lineage may be more common in a given season than another, and these subgroups are genetically unique and can change with the seasons [10]. Even while the subgroups differ genetically, they can all still cause serious infections, and the variations haven't always been linked to the range of illness severity [11]. 

The virus is rarely found in children who are asymptomatic; HMPV infection typically results in overt illness [12]. HMPV has been linked to 6 to 40% of acute respiratory illnesses in children who are hospitalized or outpatients worldwide [13].

ADULTS:

HMPV re-infection happens throughout adulthood, even though almost all populations will have had an initial HMPV infection by the age of five. In Rochester, New York, up to 13% of hospitalized individuals had HMPV [14]. HMPV infection causes higher disease severity and high rates of morbidity and mortality in the elderly, although it is usually moderate in otherwise healthy younger persons. Similar to a retrospective Canadian study, individuals aged 65 and older accounted for 46% of HMPV + cases, and 60% of these patients require hospitalization [15]. According to a later study, 50% of the elderly patients infected with HMPV + during an outbreak at a long-term care home died from bronchitis or pneumonia [16].

PATHOGENESIS:

The cotton rat, BALB/c mouse, and cynomolgus macaque are among the animal models used to examine the pathophysiology and immunogenicity of hMPV infection. When BALB/c mice and cotton rats are intravenously challenged with hMPV, the virus titer peaks in nasal turbinates on day two and in lung homogenates on days four to five after infection [17]. Although BALB/c mice display a prolonged infection with biphasic viral replication with hMPV serotype B, most tiny animal models exhibit viral clearance from the respiratory system by day 21 [18].There will frequently be several HMPV subgroups in circulation during the course of a year. One lineage may be more common in a certain season than another, and these subgroups are genetically unique and can change with the seasons [19]. All of the subgroups can still cause serious infection despite their genetic differences, and these variations have not always been linked to variations in disease severity [20]. Rarely is the virus seen in children who are asymptomatic; HMPV infection generally results in overt illness [21]. HMPV have been linked to 6–40% of acute respiratory illnesses in children who are hospitalized or outpatients worldwide [22].

CURRENT CHALLENGES IN HMPV TREATMENT

HMPV can result in serious sickness that necessitates hospitalization in some patient populations. Patients with a pre-existing heart or respiratory ailment or those with impaired immune systems are among them. Acute respiratory failure needing high-flow oxygen support is more likely to occur in these patients, and some may even worsen to the point where mechanical ventilation is necessary. Patients in these situations must be admitted to the intensive care unit for careful observation (23). The majority of hMPV infection therapies now on the market are supportive. However, several studies have suggested that ribavirin, immunoglobulin, fusion inhibitors, and tiny interfering ribonucleic acids could be used to treat and manage hMPV infection (24).Additionally, ribavirin lowers inflammation and hMPV in infected BALB/c mice. hMPV is not susceptible to palivizumab or other chemotherapeutics that target the F protein of RSV. NMSO3, a sulfated sialyl lipid, has been demonstrated to prevent hMPV replication, syncytia formation, and cell-to-cell virus transmission in culture. 

It is also known to prevent RSV replication in cell culture and in the cotton rat model (25). At this time, there is no specific treatment for HMPV infection. As of early 2022, there is just one HMPV small-molecule medication inhibitor undergoing clinical studies. Supportive treatment, similar to that used for RSV, is part of management. Although the exact rate of bactereia or bacterial lung infection linked to HMPV infection is unknown, it is thought to be minimal. Infants hospitalized for HMPV pneumonia or bronchiolitis are typically not treated with antibiotics (26). For HMPV, there are currently no approved medication therapies. Antiviral medication is not advised. Use supportive care to manage disease. Close observation and follow-up are necessary for patients with immunocompromise, elderly individuals, and infants (27).

CURRENT TREATMENT STRATEGIES

In immune-competent children and adults, seasonal URTI is often caused by the viruses respiratory syncytial virus (RSV) and human metapneumovirus. Since the immunodeficiency score index has been developed, recipients of allogeneic hematopoietic stem cell transplants are more susceptible to LRTI and mortality. The primary treatment for RSV infections in immunocompromised individuals is ribavirin, which also decreases the rate of progression of LRTI. However, its therapeutic significance in hMPV is poorly understood (28). Using a BALB/c mouse model, this study examines the effects of ribavirin, a drug that reduces hMPV tiers in vitro, on pulmonary inflammation as well as hMPV spreading (29). The effect of ribavirin on immunocompromised hosts is undetermined. By blocking viral RNA polymerase, it lowers lung inflammation and effectively treats the respiratory syncytial virus, also known as infection in lung transplant recipients. Because of their exposure to the environment and their reduced mucociliary clearance, lung transplant recipients are more susceptible to respiratory tract infections. Patients with hematologic malignancies and transplant recipients are at high risk of respiratory failure and death due to human metapneumovirus (hMPV). A lung transplant patient was reported to have had hMPV pneumonia, which was effectively treated with intravenous ribavirin(30).RSV VLP vaccine candidates, such as a vaccine incorporating RSV F or G and an influenza matrix core, have been identified. Vaccinated mice had lower virus levels in their lungs. VLPs containing stable RSV F protein ectodomains in either prefusion or post fusion configurations produced greater titers of neutralizing antibodies. These strategies might work for HMPV since a strong broadly neutralizing MAb will likely to bind to both types(31).

ADVANCEMENTS IN TREATMENT 

Researches had done on the HMPV virus to find out more about this one of the research is had on mice infected with hMPV showed poor neutrophil recruitment, delaying germ removal and increasing lung inflammation after pneumococcal infection. To explore this, a hMPV/Spn coinfection model was created in BALB/c mice. Five doses of serotype 3 WU2 were tested in male BALB/c mice aged 6–8 weeks. Mice infected with 105, 104, and 103 CFUs survived 100%, 80%, and 0%, respectively. Previously, hMPV infection did not significantly impair these mice. After intranasally infecting mice with 5x105 PFU of hMPV TN/93-32, they received three doses of Spn—106, 105, and 104 CFU/mouse—five days later. Mortality rates were 0%, 20%, and 60% at 104, 105, and 106 CFU/mouse, respectively. Due to the low death rate in animals infected alone, 106 CFUs of Spn were used for further investigations. The coinfection model was employed to evaluate the mAb PhtD3 + 7 cocktail. A dose of 7.5 mg/kg of mAb PhtD3 and mAb PhtD7 was administered two hours before Spn infection on day five after hMPV infection. Compared to the isotype mAb and PBS control groups, mAb PhtD3 + 7 provided substantial protection (100% vs. 8.3% vs. 16.6%, respectively). The PhtD3 + 7 mAb cocktail was compared to MPV467, a protective hMPV antibody. Spn and hMPV-only controls survived. The previously released mAb MPV467, which neutralizes hMPV in vivo by targeting the virus’s F protein, was added (10 mg/kg) on day three, following the same schedule. Compared to MPV467 and PBS control, mAb PhtD3 + 7 offered the highest protection (83.3% vs. 41.6% vs. 15.3%, respectively). On day five, lung viral titers decreased significantly in MPV467 treated mice. Lung and blood bacterial titers were measured at 24, 48, and 72 hours post Spn infection. Both mAb PhtD3 + 7 and MPV467 treated groups showed significant reductions in lung bacterial titers compared to PBS treated groups. No detectable bacteria were found in the blood of mice. At 48 hours, lung bacterial titers decreased in both groups, while blood bacterial titers rose. mAb PhtD3 + 7 showed no detectable bacteria, whereas MPV467 and PBS showed slight increases. At 72 hours, mAb PhtD3 + 7 treated animals had no detectable lung bacteria, while MPV467 and PBS showed further increases. Blood bacteria were undetectable in PhtD3 + 7 animals but increased in MPV467 and PBS. The hMPV/Spn coinfection model demonstrated that the PhtD3 + 7 mAb cocktail enhanced survival and decreased lung and blood bacterial levels, while mAb MPV467 provided moderate protection [32].

Human papillomavirus, or HMPV, has become a new and serious public health issue, especially in the newborn to age five age range. At some time during that phase of life, nearly all people become infected with HMPV. The danger of reinfection persists even beyond maturity, particularly for people with compromised immune systems. The development of vaccines has been transformed by developments in immunological informatics and epitope prediction. The safety and effectiveness of peptide vaccines are increased by screening target protein CTL, HTL, and B epitopes and combining them with certain adjuvant sequences. Vaccine design is validated using immunological and dynamic simulations. The effectiveness of in silicodesigned vaccines against Shigella flexneri, Streptococcus, and other infections is confirmed by animal tests. Immunoinformatic techniques work well.Unlike previous research, we chose a multi-epitope vaccine to achieve stronger targeting and minimize undesirable effects. Conserved epitopes provide broader protection against different subtypes, while T cell and B cell epitopes elicit both humoral and cellular immune responses. Additionally, epitopes from SH, M1, and M2 proteins support F epitopes, enhancing the vaccine’s functionality by targeting immune-modulatory proteins[33].

A report of a case study which tells the severity of the action of this virus and correlation with the SARS -coV 2019. 239 HMPV and 303 COVID-19 patients were included. HMPV incidence peaked in March despite a 324% increase in testing. Clinical characteristics showed 25 ICU admissions and 14 deaths. Myocardial infarction, age, and BMI were associated with increased mortality. HMPV-infected patients had similar characteristics to non-COVID-19 patients except for hospital stay. HMPV was associated with females, the elderly, and chronic conditions. Clinical outcomes were similar between the viruses during the COVID-19 period [34].

Clinical analysis revealed that four cases had coinfections with other pathogens. Our comprehensive analysis of patient samples revealed that Human Metapneumovirus, particularly the A2c genotype, significantly contributed to cases of severe acute respiratory syndrome (SARI) within our study population. This finding underscores the importance of considering Human Metapneumovirus as a potential causative agent in investigating SARI outbreaks. Which is another study done on the HMPV [35].

The isolation and studies done on the hMPV F type virus shows the mutation undergoing in the virus and the antibodies which is isolated from the human B cells We characterize the germline usage, epitopes, neutralization potencies, and binding specificities of antibodies against human metapneumovirus (hMPV) fusion protein (F). Unlike RSV-F specific monoclonal antibodies (mAbs), antibody responses to hMPV F exhibit less dominance against the antigen’s apex. Instead, the majority of potent neutralizing mAbs recognize epitopes located on the side of hMPV F. Moreover, we identify neutralizing epitopes that differ from previously defined antigenic sites on RSV F. Additionally, we discover multiple binding modes of site V and II mAbs. Interestingly, mAbs that bind preferentially to the unprocessed prefusion F exhibit poor neutralization potency. These findings shed light on the immune recognition of hMPV infection and offer novel insights for future development of hMPV antibody and vaccine strategies [36].

According to size exclusion chromatography, one (R-1b) of the three designs for RSV F was discovered to be a monodispersed, trimeric protein. The two surviving constructions showed very weak absorbance signals and aggregated in solution. The protein expression of R-1b was about 3.5 times higher than that of the prefusion-stabilized vaccine DS-Cav1, which is now in clinical use. Three (Spk-M, Spk-F, and Spk-R) out of three modified proteins and two (M-104 and M-305) out of four exhibited comparable behavior for the hMPV F and SARS-CoV-2 S, respectively. The spike designs significantly increased the protein expression of their basic construct (S-2P) by about 17 times. Comparing the hMPV F variation M-104 to its predecessor (115-BV)23, the latter showed an 8-fold increase in protein expression, matching the expression level of other highly stabilized prefusion proteins, including the DS-CavEs2 immunogen [37].

By finding these things and by the recents researches by the scientist had found out various and shocking facts about the HMPV virus the study is keep on continuing and comparing with the newer microbes (viruses) for the action and reaction of the body to the diseases which cause similar to this.

The main Challenges in Treatment Development

Especially comes the absence of approved treatments which is such a new challenge. Presently, there are no FDA-approved vaccines or antiviral medicines that treat HMPV and that makes managing the infection prevention complex. (38),(39),(40). Next, Major challenge is the immune response that comes in the picture. Because the humoral immunity does not block reinfection in adults, The immune response to HMPV is partial. So, It is important to understand T Cell Response and epitopes. (41). The other significant challenge is the genetic variability of HMPV due to having multiple circulating lineages. These make it more complex(42). Complexities of immune response along with diversified genetic variability leads us to the next challenge of developing the Vaccine. The large number of viral strains and subtypes to address complicates the development of a vaccinodial mRNA vaccine. Although multi-epitope mRNA and live attenuated vaccines show great promise, further testing is needed to prove their safety and efficacy(43),(44). Significant advances have been made in understanding the pathogenesis of and potential therapeutics for HMPV with the use of the Immunocompromised animal model, but more research needs to be undertaken in terms of this model (45). Drug repurposing still faces volume issues with having good candidates with low toxicity in it.Some ingredients have shown certain promising results in invitro, but it is necessary to check further on the safety and efficacy(46).The viral fusion (F) protein is crucial for entry and a primary target for neutralizing antibodies, with natural infection eliciting a diverse humoral response (47). Innate immune components play vital roles in regulating HMPV pathogenesis and resolution (48). Drug repurposing efforts have identified potential anti-HMPV candidates, including entry inhibitors and post-entry inhibitors, with mycophenolic acid showing promising results (49). The F protein remains a key target for antiviral strategies, with various inhibitors being explored for future drug design (50). These findings contribute to our understanding of HMPV and guide ongoing efforts in vaccine and therapeutic development. The biggest nonexistence of drug therapies has provided room for the utilization of drug repurposing and making better vaccines and animal models for research; in most cases, it is ideal to reduce the health magnitude globally coming up in HMPV infection.

FUTURE PRESPECTIVES

To mitigate the impact of HMPV, future research should prioritize:

• Development of effective vaccines and antivirals.
• Improved diagnostic tools for early detection.
• Global surveillance systems to monitor outbreaks and viral evolution [51].

OTHER FACTORS SHOULD BE CONSIDERED IN DESIGNING

FUTURE VACCINES;

Although the F protein is believed to be a major factor determining the immunogenicity of hMPV, the identification of viral antigens that activate both protective cytotoxic T lymphocytes (CTL) and humoral responses is still necessary to develop a successful vaccination strategy. Indeed, several CTL peptides have been proved to be important for CD8+ CTL responses to hMPV challenge. These peptides are 164VGALIFTKL172 from N for H-2b mice, 56CYLENIEII64 from the M2-2 protein for H-2d mice, 35KLILALLTFL44 from the SH protein and 32SLILIGITTL41 from the G protein for HLA-A*0201 transgenic mice. Vaccination with these hMPV CTL epitopes upregulates expression of Th1-type cytokines in the lungs and peribronchial lymph nodes of hMPV-challenged mice, resulting in reduced viral titres and disease in mouse models (Herd et al., 2006). Recently, dominant and subdominant hMPV H-2d epitopes were screened and identified (Melendi et al., 2007) [52].

CONSTRUCTION OF MULTI-EPITOPE mRNA VACCINE AND VACCINE VECTOR;

Reverse translation and optimization were possessed on Jcat server, after improvement, a 2573 bp length cDNA was captured, which including full-length epitope vaccine as well as tPA and MITD sequence, its CAI value is 1.0 and its GC content is 49.98, both lies in an ideal range, suggesting good density and thermos-stability. After connecting with UTR sequence, the fulllength DNA has 2624 bps. Then, RNA fold predicted its free energy of the thermodynamic ensemble (free energy of the secondary structure of vaccine mRNA) to be −796.96 kcal/mol, and the plasmid structure’s minimum free energy is −507.49 kcal/mol, graphical output can be found in supplement materials. The results predicted revealed the stability of the multi-epitope mRNA vaccine Finally, the DNA sequence of mRNA vaccine was inserted into Pet28a (+) plasmid between BamHI and XhoI with gensmart server to construct the expression vector[53].

CURRENT APPROACHES TO THE DEVELOPMENT OF HMPV VACCINE;

As was mentioned earlier, classical approaches to the development of HMPV vaccines were shown to be ineffective. Current strategies for rational HMPV vaccine design include the use of recombinant viral proteins (perhaps in a VLP formulation), recombinant live attenuated HMPV vaccines, and viral-vectored constructs [54]. Recently, the replication and transcription of HMPV in bronchial epithelial-derived immortal cells was analyzed and it was deduced that like other filoviruses and rhabdoviruses, formation of cytoplasmic inclusion bodies is required for HMPV genome replication and transcription[55].

REFERENCE

1. Uddin S, Thomas M. Human Metapneumovirus. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. 45–51. 
2. Panda S, Mohakud NK, Pena L, Kumar S. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis. 2014. 25:45-52.
3. Divarathna MVM, Rafeek RAM, Noordeen F. A review on epidemiology and impact of human metapneumovirus infections in children using TIAB search strategy on PubMed and PubMed Central articles. Rev Med Virol. 2020 Jan;30(1): e2090. 
4. Zhang Y, Xu J, Miranda-Katz M, Sojati J, Tollefson SJ, Manni ML, Alcorn JF, Sarkar SN, Williams JV. Distinct roles for type I and type III interferons in virulent human metapneumovirus pathogenesis. PLoS Pathog. 2024 Feb 5;20(2): e1011840. 
5. Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev. 2006 Jul;19(3):546-57.
6. Wang C, Wei T, Ma F, Wang H, Guo J, Chen A, Huang Y, Xie Z, Zheng L. Epidemiology and genotypic diversity of HMPV   in paediatric patients with acute respiratory infection in Beijing, China. Virol J. 2021 Feb 18;18(1):40. 
7. Yi L, Zou L, Peng J, Yu J, Song Y, Liang L, Guo Q, Kang M, Ke C, Song T, Lu J, Wu J. Epidemiology, evolution and transmission of human metapneumovirus in Guangzhou China, 2013-2017. Sci Rep. 2019 Oct 1;9(1):14022. 
8. Zhang L, Liu W, Liu D, Chen D, Tan W, Qiu S, Xu D, Li X, Liu T, Zhou R. Epidemiological and clinical features of human metapneumovirus in hospitalised paediatric patients with acute respiratory illness: a cross-sectional study in Southern China, from 2013 to 2016. BMJ Open. 2018 Feb 6;8(2). 
9. Anderson EJ, Simo?es EA, Buttery JP, et al. Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection. J Pediatric Infect Dis Soc. 2012;1(3):212–22. 
10. Williams JV, Wang CK, Yang CF, et al: The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis. 2006;193(3):387–95. 
11. Wei HY, Tsao KC, Huang CG, et al.: Clinical features of different genotypes/genogroups of human metapneumovirus in hospitalized children. J Microbiol Immunol Infect. 2013;46(5):352–7. 
12. Williams JV, Harris PA, Tollefson SJ, et al.: Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med.2004;350(5):443–50. 
13. Madhi SA, Ludewick H, Abed Y, et al.: Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV1)-infected and HIV-1-uninfected African infants. Clin Infect Dis. 2003;37(12):1705–10. 
14. Walsh EE, Peterson DR, Falsey AR: Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168(22):2489–96. 
15. Boivin G, Abed Y, Pelletier G, et al.: Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. 2002;186(9):1330–4. 
16. Boivin G, De Serres G, Hamelin ME, et al.   An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007;44(9):1152–8. 
17. Hamelin M.E., Yim K., Kuhn K.H. Pathogenesis of human metapneumovirus lung infection in BALB/c mice and cotton rats. J Virol. 2005;79(14):8894–8903. 
18. Alvarez R., Tripp R.A. The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice. J Virol. 2005;79(10):5971–5978. 
19. (2023, September 21). A decade of human metapneumovirus in hospitalized children with acute. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514255/
20. (2019, April 15). Rates of asymptomatic respiratory virus infection across age groups. https://www.cambridge.org/core/journals/epidemiology-and-infection/article/rates-ofasymptomatic-respiratory-virus-infection-across-agegroups/D8E75BDC5B16AEC88DB57CD9B291BB37
21. (2023, September 21). A decade of human metapneumovirus in hospitalized children with acute. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514255/
22. Boivin G, De Serres G, Hamelin ME, et al.  An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007;44(9):1152–8. 
23. 23.Uddin S, Thomas M. Human Metapneumovirus. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32809745.
24. Panda S, Mohakud NK, Pena L, Kumar S. Human metapneumovirus: review of an important respiratory pathogen. Int J Infect Dis. 2014 Aug; 25:45-52. 
25. Hermos CR, Vargas SO, McAdam AJ. Human metapneumovirus. Clin Lab Med. 2010 Mar;30(1):131-48. 
26. Kitanovski L, Kopriva S, Pokorn M, Dolni?ar MB, Raji? V, Stefanovi? M, Jazbec J. Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol. 2013 Oct;35(7):e311-3.
27. Lei Z, Feng G, Wang Z, Ning Z. Noncoding RNAs and Virus and Treatment in Allergic Rhinitis. Evid Based Complement Alternat Med. 2022 Oct 15; 2022:1979447. Retraction in: Evid Based Complement Alternat Med. 2023 Aug 9; 2023:9898150. 
28. Akhmedov M, Wais V, Sala E, et al. Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes. Transpl Infect Dis. 2020; 22: e13276
29. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006 Feb;50(2):774-7. 
30. Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, Kwak EJ, Rinaldo CR Jr, Pilewski JM, McCurry KR, Husain S. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007 Aug;26(8):862-4.
31. Wen SC, Williams JV. New Approaches for Immunization and Therapy against Human Metapneumovirus. Clin Vaccine Immunol. 2015 Aug;22(8):858-66. 
32. Gingerich A, Mahoney L, McCormick AL, Miller RJ, Mousa J. Human monoclonal antibodies protect against viral-mediated pneumococcal superinfection. Front Immunol. 2024 Jun 12; 15:1364622
33. Ma, S., Zhu, F., Xu, Y., Wen, H., Rao, M., Zhang, P., … Pan, P. (2024). Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus. Human Vaccines & Immuno therapeutics, 20(1)
34. Jongbloed, M., Leijte, W. T., Linssen, C. F. M., van den Hoogen, B. G., van Gorp, E. C. M., & de Kruif, M. D. (2021). Clinical impact of human metapneumovirus infections before and during the COVID-19 pandemic. Infectious Diseases, 53(7), 488–497. 
35. P., P., Shetty, U., Parida, P., Varamballi, P., Mukhopadhyay, C., & N, S. (2024). Molecular detection and genotyping of HMPV in patients with severe acute respiratory infection in India. Annals of Medicine, 56(1). 
36. Xiao, X., Fridman, A., Zhang, L. et al. Profiling of hMPV F-specific antibodies isolated from human memory B cells. Nat Commun13, 2546 (2022). 
37. Gonzalez, K.J., Huang, J., Criado, M.F. et al. A general computational design strategy for stabilizing viral class I fusion proteins. Nat Commun 15, 1335 (2024). 
38. Boggs, K., Edmonds, K., Cifuentes-Muñoz, N., Najjar, F., Ossandón, C., Roe, M., Wu, C., Moncman, C., Creamer, T., Amarasinghe, G., Leung, D., & Dutch, R. (2022). Human Metapneumovirus Phosphoprotein Independently Drives Phase Separation and Recruits Nucleoprotein to Liquid-Like Bodies. mBio, 13. 
39. Lan, J., Parks, O., Zhang, Y., Walters, S., Sojati, J., & Williams, J. (2022). Identification and Characteristics of HLA-restricted HMPV-specific CD8+ T cells. The Journal of Immunology. 
40. Van Den Bergh, A., Guillon, P., Von Itzstein, M., Bailly, B., & Dirr, L. (2022). Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection. Antimicrobial Agents and Chemotherapy, 66. 
41. Lan, J., Parks, O., Zhang, Y., Walters, S., Sojati, J., & Williams, J. (2022). Identification and Characteristics of HLA-restricted HMPV-specific CD8+ T cells. The Journal of Immunology. 
42. Groen, K., Van Nieuwkoop, S., Meijer, A., Van Der Veer, B., Van Kampen, J., Fraaij, P., Fouchier, R., & Van Den Hoogen, B. (2022). Emergence and Potential Extinction of Genetic Lineages of Human Metapneumovirus between 2005 and 2021. mBio, 14. 
43. Tian, C., Lei, G., Fang, S., Deng, Z., Hao, Y., Cong, L., Xinyu, L., Wei, H., Tan, L., Yan, N., & Yang, P. (2023). A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice. Frontiers in Microbiology, 13. 
44. Dubois, J., Pizzorno, A., Cavanagh, M., Padey, B., De Lamballerie, C., Uyar, O., Venable, M., Carbonneau, J., Traversier, A., Julien, T., Couture, C., Lina, B., Hamelin, M., Terrier, O., Rosa-Calatrava, M., & Boivin, G. (2019). Strain-Dependent Impact of G and SH Deletions Provide New Insights for Live-Attenuated HMPV Vaccine Development. Vaccines, 7. 
45. Yim, K., Mousa, J., Blanco, J., Kim, S., & Boukhvalova, M. (2023). Human Metapneumovirus (hMPV) Infection and MPV467 Treatment in Immunocompromised Cotton Rats Sigmodon hispidus. Viruses, 15. 
46. Van Den Bergh, A., Guillon, P., Von Itzstein, M., Bailly, B., & Dirr, L. (2022). Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection. Antimicrobial Agents and Chemotherapy, 66. 
47. Rush, S.A., Brar, G., Hsieh, C.L., Chautard, E., Rainho-Tomko, J.N., Slade, C.D., Bricault, C.A., Kume, A., Kearns, J., Groppo, R. and Mundle, S.T., 2022. Characterization of prefusionF-specific antibodies elicited by natural infection with human metapneumovirus. Cell Reports, 40(12).
48. 48.Andrade, C.A., Pacheco, G.A., Gálvez, N.M., Soto, J.A., Bueno, S.M. and Kalergis, A.M., 2020. Innate immune components that regulate the pathogenesis and resolution of hRSV and hMPV infections. Viruses, 12(6), p.637.
49. Van Den Bergh, A., Guillon, P., Von Itzstein, M., Bailly, B., & Dirr, L. (2022). Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection. Antimicrobial Agents and Chemotherapy, 66. 
50. Van Den Bergh, A., Guillon, P., Von Itzstein, M., Bailly, B., & Dirr, L. (2022). Drug Repurposing for Therapeutic Discovery against Human Metapneumovirus Infection. Antimicrobial Agents and Chemotherapy, 66. 
51. Riju aikkal, Human Metapneumovirus (HMPV): Epidemiology, Clinical Manifestations, and Future Perspectives, Independent Researcher, India
52. J. Ren,1 T. Phan1 and X. Bao1,2,3, Recent vaccine development for human metapneumovirus. Journal of General Virology (2015), 96, 1515–1520.
53. Shiyang Ma, Fei Zhu, Yizhong Xu, Haicheng Wen, Mingjun Rao, Peipei Zhang, Wenzhong Peng, Yanhui Cui, Hang Yang, Caixia Tan, Jie Chen & Pinhua Pan. Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus. HUMAN VACCINES & IMMUNOTHERAPEUTICS 2023, VOL. 19, NO. 3, 2293300 
54. Ekaterina Stepanova, Victoria Matyushenko, Larisa Rudenko and Irina Isakova-Sivak*. Prospects of and Barriers to the Development of Epitope-Based Vaccines against Human Metapneumovirus. Pathogens 2020, 9, 481.
55. Prashant Kumar, Mansi Srivastava. Prophylactic and therapeutic approaches for human metapneumovirus. Prophylactic and therapeutic approaches for human metapneumovirus.